Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-glutamic acid is the D-enantiomer of glutamic acid, an optically active amino acid with the configuration (R)-2-aminopentanedioic acid. Unlike the more common L-form, which is a key neurotransmitter and involved in protein synthesis in humans, D-glutamic acid is primarily found in bacterial cell walls as a component of peptidoglycan. It plays an essential role in bacterial physiology by being incorporated into peptidoglycan precursors via specific enzymes such as murD and glutamate racemase. Industrially, it is used for research purposes and as a building block for biodegradable polymers like polyglutamic acids. In mammals, it has limited physiological roles but can act as an inhibitor of glutathione synthesis[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-glutamic acid.